UTHR

United Therapeutics Corp

Oct 15 • 04:00PM ET

432.19

-1.42 -0.33 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: AMGN PFE LLY MRK REGN JNJ BMY VRTX GILD BIIB

| Held by: IJH VTI VB VBR XMHQ VXF MDY XBI IBB IJK

Index	-	P/E	16.88	EPS (ttm)	25.61	Insider Own	3.21%	Shs Outstand	45.22M	Perf Week	-3.73%
Market Cap	19.55B	Forward P/E	14.70	EPS next Y	29.40	Insider Trans	-23.53%	Shs Float	43.77M	Perf Month	8.60%
Enterprise Value	16.50B	PEG	2.58	EPS next Q	7.32	Inst Own	97.07%	Short Float	5.01%	Perf Quarter	45.36%
Income	1.24B	P/S	6.35	EPS this Y	10.40%	Inst Trans	-1.20%	Short Ratio	2.79	Perf Half Y	51.74%
Sales	3.08B	P/B	2.72	EPS next Y	8.07%	ROA	16.98%	Short Interest	2.19M	Perf YTD	22.49%
Book/sh	158.65	P/C	6.41	EPS next 5Y	6.53%	ROE	19.30%	52W High	459.48 -5.94%	Perf Year	20.65%
Cash/sh	67.41	P/FCF	18.30	EPS past 3/5Y	34.80% -	ROIC	17.31%	52W Low	266.98 61.88%	Perf 3Y	109.85%
Dividend Est.	-	EV/EBITDA	10.65	Sales past 3/5Y	19.52% 14.71%	Gross Margin	88.98%	Volatility	2.36% 2.89%	Perf 5Y	312.04%
Dividend TTM	-	EV/Sales	5.36	EPS Y/Y TTM	19.89%	Oper. Margin	47.75%	ATR (14)	12.53	Perf 10Y	251.80%
Dividend Ex-Date	-	Quick Ratio	6.94	Sales Y/Y TTM	17.62%	Profit Margin	40.36%	RSI (14)	56.94	Recom	1.59
Dividend Gr. 3/5Y	- -	Current Ratio	7.26	EPS Q/Q	9.45%	SMA20	-0.66%	Beta	0.77	Target Price	497.92
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	11.71%	SMA50	13.63%	Rel Volume	0.82	Prev Close	433.61
Employees	1305	LT Debt/Eq	0.00	Earnings	Jul 30 BMO	SMA200	29.84%	Avg Volume	786.04K	Price	432.19
IPO	Jun 17, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	-12.13% -0.41%	Trades		Volume	642,644	Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-26-25	Initiated	RBC Capital Mkts	Outperform	$569
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight	$405
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral	$314
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125
Mar-10-20	Upgrade	Jefferies	Hold → Buy	$123

Show Previous Ratings

Today 07:00AM	United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 (Business Wire)
Oct-13-25 07:00AM	United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting (Business Wire)
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Sep-30-25 04:38PM	Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals (Zacks)
09:46AM	Loading…
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-19-25 11:53AM	Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE? (Zacks)
07:00AM	United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis (Business Wire)
12:46AM	1 Momentum Stock to Target This Week and 2 We Brush Off (StockStory)
12:03AM	3 Big Reasons to Love United Therapeutics (UTHR) (StockStory)
Sep-16-25 07:00AM	United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum (Business Wire)
Sep-12-25 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress (Business Wire)
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-10-25 02:46PM	United Therapeutics Price Strength Rating Jumps; Stock Soared 33% Last Week (Investor's Business Daily)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
09:00AM	Loading…
09:00AM	Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint (TipRanks)
08:52AM	Pharma, Opendoor, Tesla: Trending Stocks (Yahoo Finance Video)
06:30AM	Lung Disease Breakthrough Boosts United Therapeutics and its Rivals (The Daily Upside)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily) +32.83%
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
07:00AM	United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis (Business Wire)
Aug-29-25 11:30AM	Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report? (Zacks)
07:00AM	United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-13-25 12:05AM	5 Insightful Analyst Questions From United Therapeutics's Q2 Earnings Call (StockStory)
Aug-12-25 11:40PM	UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty (StockStory)
04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
Aug-11-25 04:15PM	3D Systems Reports Second Quarter 2025 Financial Results (GlobeNewswire)
11:32AM	Merck's Narrowed 2025 Sales View: What it Means After Q2 Results? (Zacks)
Aug-01-25 07:00AM	United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program (Business Wire) +7.13%
10:15AM	Loading…
Jul-31-25 10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
Jul-30-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks) -5.25%
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics (Zacks)
07:35AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
06:46AM	United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates (StockStory)
06:36AM	United Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results (Business Wire)
Jul-28-25 11:13PM	What To Expect From United Therapeutics's (UTHR) Q2 Earnings (StockStory)
10:00AM	Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline (Zacks)
02:07AM	Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT (Insider Monkey)
Jul-25-25 10:42PM	United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial (Insider Monkey)
Jul-24-25 09:50AM	United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily)
Jul-23-25 10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jul-21-25 06:32PM	United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag (Insider Monkey)
Jul-18-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Jul-16-25 07:00AM	United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025 (Business Wire)
Jul-15-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:59AM	Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling (Insider Monkey)
Jul-11-25 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Jul-10-25 11:26PM	UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) (Insider Monkey)
Jul-09-25 12:33AM	1 Value Stock with Impressive Fundamentals and 2 to Turn Down (StockStory)
Jul-07-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jul-04-25 12:10PM	Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-03-25 08:30AM	MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE (Zacks)
Jul-02-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jun-28-25 04:16AM	United Therapeutics Announces World's First Bioengineered External Liver Treatment in Clinical Study (Insider Monkey)
Jun-26-25 09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Jun-25-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
07:40AM	5 Must-Read Analyst Questions From United Therapeutics's Q1 Earnings Call (StockStory)
Jun-24-25 12:20PM	MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal (Zacks)
07:00AM	United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver (Business Wire)
Jun-23-25 07:00AM	United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension (Business Wire)
Jun-13-25 02:32AM	United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock? (Zacks)
Jun-11-25 11:04AM	Insmed Stock Jumps 29% on Encouraging PAH Study Results (Zacks)
Jun-10-25 04:07PM	Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia (Investor's Business Daily) -14.32%
02:48PM	Insmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial Results (Investopedia)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-09-25 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jun-06-25 11:31AM	Catalyst (CPRX) Up 11.4% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 11:30AM	Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound? (Zacks)
May-30-25 11:31AM	Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report? (Zacks)
May-11-25 05:01PM	Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons' Renaissance Technologies? (Insider Monkey)
May-09-25 03:21AM	Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... (GuruFocus.com)
12:01AM	3 Big Reasons to Love United Therapeutics (UTHR) (StockStory)
May-07-25 12:33AM	3 Market-Beating Stocks with Solid Fundamentals (StockStory)
May-05-25 04:06PM	Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month (Seeking Alpha)
May-02-25 07:15AM	The Top 3 Stock Picks at the World's Greatest Hedge Fund (MarketBeat)
May-01-25 07:57AM	UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales (Zacks)
03:10AM	United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
12:37AM	1 Value Stock Worth Investigating and 2 to Brush Off (StockStory)
12:34AM	Q1 2025 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
Apr-30-25 01:09PM	United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
07:35AM	United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates (Zacks)
06:35AM	United Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 03:10AM	United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Apr-28-25 10:00AM	Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards? (Zacks)
Apr-23-25 10:01AM	United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-22-25 03:27AM	Polaris Global Equity Composite Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference (Business Wire)
Apr-16-25 07:00AM	United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025 (Business Wire)
Apr-11-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Apr-10-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Apr-08-25 12:10PM	Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-07-25 06:38AM	Liquidia: United Therapeutics Has The Last Laugh (Seeking Alpha)
05:11AM	Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4 (StockStory)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 13 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 15 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 14 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 15 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 13 '25	Sale	440.43	4,000	1,761,730	130	Oct 15 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 14 '25	Sale	437.47	4,000	1,749,874	130	Oct 15 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Oct 13 '25	Option Exercise	139.13	22,500	3,130,504	14,625	Oct 15 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Oct 13 '25	Sale	440.35	22,500	9,907,963	0	Oct 15 04:30 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 15 '25	Proposed Sale	435.29	4,000	1,741,164		Oct 15 03:53 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 13 '25	Proposed Sale	440.43	4,000	1,761,732		Oct 14 03:24 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 09 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 10 05:03 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 10 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 10 05:03 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 09 '25	Sale	448.91	4,000	1,795,655	130	Oct 10 05:03 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 10 '25	Sale	444.70	4,000	1,778,788	130	Oct 10 05:03 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 10 '25	Proposed Sale	444.70	4,000	1,778,788		Oct 10 04:56 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 09 '25	Proposed Sale	448.91	4,000	1,795,655		Oct 09 04:50 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 08 '25	Proposed Sale	450.86	4,000	1,803,449		Oct 08 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 07 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 08 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 08 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 08 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 07 '25	Sale	451.83	4,000	1,807,320	130	Oct 08 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 08 '25	Sale	450.86	4,000	1,803,449	130	Oct 08 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Oct 06 '25	Option Exercise	139.13	22,500	3,130,504	14,625	Oct 07 04:32 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Oct 06 '25	Sale	450.24	22,500	10,130,439	0	Oct 07 04:32 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 07 '25	Proposed Sale	451.83	4,000	1,807,320		Oct 07 04:12 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 03 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 06 05:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 06 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 06 05:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 06 '25	Sale	449.69	4,000	1,798,765	130	Oct 06 05:35 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 03 '25	Sale	446.21	4,000	1,784,847	130	Oct 06 05:35 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 06 '25	Proposed Sale	449.69	4,000	1,798,765		Oct 06 05:25 PM
Michael Benkowitz	Officer	Oct 06 '25	Proposed Sale	453.07	90,000	40,776,300		Oct 06 04:23 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 03 '25	Proposed Sale	446.21	4,000	1,784,847		Oct 03 04:55 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 02 '25	Proposed Sale	434.88	4,000	1,739,525		Oct 02 05:24 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 01 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 02 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 02 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 02 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 02 '25	Sale	434.88	4,000	1,739,525	130	Oct 02 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 01 '25	Sale	425.45	4,000	1,701,797	130	Oct 02 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 02 '25	Option Exercise	135.42	11,000	1,489,620	47,781	Oct 02 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 02 '25	Sale	436.60	11,000	4,802,574	36,781	Oct 02 04:30 PM
PAUL MAHON	Officer	Oct 02 '25	Proposed Sale	436.60	11,000	4,802,572		Oct 02 04:01 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Oct 01 '25	Proposed Sale	425.45	4,000	1,701,797		Oct 01 05:02 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 29 '25	Option Exercise	139.13	22,500	3,130,504	14,625	Oct 01 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 29 '25	Sale	421.80	22,500	9,490,512	0	Oct 01 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 29 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 01 08:00 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 30 '25	Option Exercise	120.26	4,000	481,040	4,130	Oct 01 08:00 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 29 '25	Sale	425.63	4,000	1,702,527	130	Oct 01 08:00 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 30 '25	Sale	422.84	4,000	1,691,358	130	Oct 01 08:00 AM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 30 '25	Proposed Sale	472.82	4,000	1,891,278		Sep 30 01:06 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 29 '25	Proposed Sale	425.61	4,000	1,702,447		Sep 29 03:43 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 25 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 29 07:41 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 26 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 29 07:41 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 25 '25	Sale	430.93	4,000	1,723,739	130	Sep 29 07:41 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 26 '25	Sale	428.22	4,000	1,712,891	130	Sep 29 07:41 AM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 26 '25	Proposed Sale	428.20	4,000	1,712,811		Sep 26 02:57 PM
CAUSEY CHRISTOPHER	Director	Sep 24 '25	Option Exercise	119.76	1,000	119,760	5,865	Sep 25 04:31 PM
CAUSEY CHRISTOPHER	Director	Sep 24 '25	Sale	440.00	1,000	440,000	4,865	Sep 25 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 23 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 25 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 24 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 25 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 24 '25	Sale	434.12	4,000	1,736,489	130	Sep 25 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 23 '25	Sale	418.15	4,000	1,672,593	130	Sep 25 04:30 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 25 '25	Proposed Sale	430.91	4,000	1,723,659		Sep 25 11:54 AM
CHRISTOPHER CAUSEY	Director	Sep 24 '25	Proposed Sale	440.00	1,000	440,000		Sep 24 05:37 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 24 '25	Proposed Sale	434.10	4,000	1,736,408		Sep 24 04:23 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 22 '25	Option Exercise	139.13	22,500	3,130,504	14,625	Sep 24 06:35 AM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 22 '25	Sale	416.35	22,500	9,367,954	0	Sep 24 06:35 AM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 23 '25	Proposed Sale	404.42	4,000	1,617,665		Sep 23 04:01 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 22 '25	Proposed Sale	417.30	4,000	1,669,212		Sep 22 04:41 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 19 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 22 04:39 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 22 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 22 04:39 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 22 '25	Sale	417.30	4,000	1,669,213	130	Sep 22 04:39 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 19 '25	Sale	411.08	4,000	1,644,310	130	Sep 22 04:39 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 19 '25	Proposed Sale	411.08	4,000	1,644,310		Sep 19 05:00 PM
Olian Judy D.	Director	Sep 19 '25	Sale	415.43	1,800	747,768	5,045	Sep 19 04:49 PM
JUDY OLIAN	Director	Sep 19 '25	Proposed Sale	415.43	1,800	747,768		Sep 19 04:04 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 18 '25	Option Exercise	135.42	11,000	1,489,620	47,781	Sep 18 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 18 '25	Sale	406.17	11,000	4,467,908	36,781	Sep 18 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 17 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 18 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 18 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 18 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 18 '25	Sale	404.42	4,000	1,617,665	130	Sep 18 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 17 '25	Sale	400.17	4,000	1,600,687	130	Sep 18 04:30 PM
PAUL MAHON	Officer	Sep 18 '25	Proposed Sale	406.17	11,000	4,467,907		Sep 18 04:09 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 18 '25	Proposed Sale	404.42	4,000	1,617,665		Sep 18 03:28 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 16 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 17 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 16 '25	Sale	400.27	4,000	1,601,062	130	Sep 17 04:30 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 17 '25	Proposed Sale	400.17	4,000	1,600,687		Sep 17 03:08 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 15 '25	Option Exercise	139.13	22,500	3,130,504	14,625	Sep 17 06:02 AM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 15 '25	Sale	400.56	22,500	9,012,624	0	Sep 17 06:02 AM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 16 '25	Proposed Sale	400.27	4,000	1,601,062		Sep 16 04:34 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 12 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 16 07:44 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 15 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 16 07:44 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 12 '25	Sale	403.98	4,000	1,615,900	130	Sep 16 07:44 AM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 15 '25	Sale	397.88	4,000	1,591,536	130	Sep 16 07:44 AM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 15 '25	Proposed Sale	397.88	4,000	1,591,536		Sep 15 04:32 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 12 '25	Proposed Sale	403.97	4,000	1,615,898		Sep 12 02:14 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 10 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 11 07:41 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 11 '25	Option Exercise	120.26	4,000	481,040	4,130	Sep 11 07:41 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 10 '25	Sale	398.72	4,000	1,594,873	130	Sep 11 07:41 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Sep 11 '25	Sale	397.23	4,000	1,588,904	130	Sep 11 07:41 PM
ROTHBLATT MARTINE A	Founder, Chairperson and Chief	Sep 11 '25	Proposed Sale	397.23	4,000	1,588,904		Sep 11 01:32 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Sep 10 '25	Proposed Sale	398.72	4,000	1,594,873		Sep 10 04:50 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 09 '25	Option Exercise	397.41	11,375	4,520,573	11,375	Sep 10 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 08 '25	Option Exercise	139.13	5,000	695,668	3,250	Sep 10 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Sep 09 '25	Sale	397.41	11,375	4,520,574	0	Sep 10 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UTHR

United Therapeutics Corp

Upgrade your FINVIZ experience